(Q37168027)

18 August 2017

1 reference

title

Current treatment of lupus nephritis (English)

1 reference

18 August 2017

2

E M Ginzler

1 reference

18 August 2017

F A Houssiau

1

1 reference

18 August 2017

publication date

1 May 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

17

1 reference

18 August 2017

issue

5

1 reference

18 August 2017

page(s)

426-430

1 reference

Management of lupus nephritis: an update

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090029

Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090029

Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090029

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090029

Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090029

Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090029

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090029

Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090029

Short course of weekly low-dose intravenous pulse cyclophosphamide in the treatment of lupus nephritis: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090029

Short term effects of intravenous pulses of cyclophosphamide in the treatment of connective tissue disease crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090029

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090029

Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090029

Sequential therapies for proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090029

Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090029

Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090029

Abetimus sodium (riquent) for the prevention of nephritic flares in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090029

Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090029

21 January 2018

Identifiers

DOI

10.1177/0961203308090029

1 reference

18 August 2017

1 reference